← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

ROS1 Rearranged NSCLC

MONDO:0005061 Curated 2026-07-04T00:00:00Z 9 harmonized findings
falcon · 21 citations openscientist · 34 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

ROS1-rearranged NSCLC is a rare molecular subset of lung adenocarcinoma (~1-2% of NSCLC) defined by somatic ROS1 gene fusions that create a constitutively active oncogenic kinase, occurring predominantly in never-smokers with adenocarcinoma histology.

UNANIMOUS INTEGRATED
pathophysiologygenetic_factorepidemiology
ProviderStanceScoreEvidence
falcon CONCORDANT 95% A molecular subset of NSCLC (1–2.5%) harboring molecular rearrangements of the tyrosine kinase gene ROS1 is defined as ROS1-positive and is almost exclusively diagnosed in patients with lung adenocarcinoma histology, predominantly nonsmokers.
Falcon states the defining fusion, the 1-2.5% frequency, adenocarcinoma histology, and never-smoker enrichment directly.
DOI:10.3390/onco3030014
openscientist CONCORDANT 95% Accounting for 1–2% of all NSCLC cases, this disease predominantly affects younger, never-smoking females and is characterized by adenocarcinoma histology with distinctive mucinous cribriform and signet ring cell patterns.
OpenScientist matches the 1-2% frequency and adenocarcinoma/never-smoker framing and adds the female predominance and characteristic histologic patterns.
PMID:40171848, PMID:41548253

The constitutively active ROS1 fusion kinase signals in a ligand-independent manner through canonical RTK effector cascades (RAS-MAPK, PI3K-AKT-mTOR) to drive proliferation and survival, producing oncogene addiction to ROS1.

UNANIMOUS INTEGRATED
pathophysiologygene_function
ProviderStanceScoreEvidence
falcon CONCORDANT 80% and downstream pathway activation (e.g., MAPK), driving proliferation/survival.
Falcon describes constitutive ROS1 kinase signaling driving downstream MAPK activation and proliferation/survival, but names only the MAPK arm.
DOI:10.3390/onco3030014
openscientist CONCORDANT 90% The oncogenic ROS1 fusion proteins activate downstream signaling through STAT3, SHP2 (with uniquely strong phosphorylation compared to ALK fusions), RAS-MAPK, and PI3K-AKT-mTOR pathways, driving uncontrolled cellular proliferation and survival.
OpenScientist enumerates the same RAS-MAPK and PI3K-AKT-mTOR effectors and adds STAT3 and SHP2 nodes.

All ROS1 fusions converge on STAT3 activation and directly engage/phosphorylate SHP2 more strongly than ALK fusions, a signaling feature that distinguishes ROS1 from ALK biology and nominates SHP2 as a therapeutic vulnerability.

SINGLE LEAD
pathophysiologygene_function
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% All ROS1 fusions converge on STAT3 activation and directly interact with SHP2, with significantly greater SHP2 phosphorylation than ALK fusions. This distinguishes ROS1 from ALK biology and identifies SHP2 as a therapeutic vulnerability.
OpenScientist makes the SHP2/STAT3 convergence and ROS1-vs-ALK distinction explicit and frames SHP2 inhibition as a rational combination strategy.
PMID:41790556, PMID:34158345
falcon SILENT —
Falcon's therapy-focused report describes ROS1 signaling only through canonical MAPK; it does not mention STAT3 or SHP2 convergence or the ROS1-vs-ALK signaling distinction.

ROS1+ NSCLC has a distinctive demographic profile relative to unselected NSCLC: enriched in younger patients, females, and never-smokers.

UNANIMOUS INTEGRATED
epidemiologyphenotype
ProviderStanceScoreEvidence
falcon CONCORDANT 75% TRUST-I: 73% never smoked; 58% female
Falcon reports TRUST-I cohort demographics (median age 55, 58% female, 73% never-smokers) consistent with the enrichment claim.
DOI:10.1200/JCO.24.00731
openscientist CONCORDANT 95% Median age 50–56 years, 58.9% female, 75.7% never-smokers, 98.1% adenocarcinoma. Statistically significant differences versus ROS1-negative NSCLC in age (p < 0.01), sex (p < 0.01), and smoking status (p < 0.01).
OpenScientist quantifies the same female/younger/never-smoker enrichment with statistical significance versus ROS1-negative NSCLC.
PMID:30468296, PMID:29883837

CNS tropism is a hallmark of ROS1+ NSCLC, with brain metastases present in a substantial fraction of patients at diagnosis, making intracranial activity a central consideration in TKI selection.

UNANIMOUS INTEGRATED
phenotypetreatment
ProviderStanceScoreEvidence
falcon CONCORDANT 85% involvement is common: 20–40% have brain metastases at diagnosis per 2024 review, and intracranial endpoints are central to modern ROS1 TKI development
Falcon reports 20-40% brain metastases at diagnosis and ties intracranial endpoints to ROS1 TKI development.
DOI:10.1093/oncolo/oyae205
openscientist CONCORDANT 85% High rate of brain metastases (~22–36% at diagnosis), a hallmark of the disease and a key clinical challenge
OpenScientist calls high brain-metastasis rate at diagnosis (22-36%) a hallmark; the baseline fraction differs slightly from Falcon's 20-40% but is not a contradiction.

Acquired resistance to ROS1 TKIs is near-universal and heterogeneous, driven by on-target kinase-domain mutations (the solvent-front G2032R most common, plus L2086F and L2026M) and off-target bypass pathways (notably MET), so serial molecular profiling at progression guides sequential therapy.

UNANIMOUS INTEGRATED
genetic_factorpathophysiologytreatment
ProviderStanceScoreEvidence
falcon CONCORDANT 75% and subsequent therapy decisions should account for progression pattern and (when known) resistance mechanism
Falcon states resistance invariably develops and lists on-target solvent-front G2032R plus off-target MET alterations, with therapy choice driven by the resistance mechanism.
DOI:10.1093/oncolo/oyae205, DOI:10.1158/1078-0432.CCR-24-0949
openscientist CONCORDANT 90% On-target mutations (G2032R, L2086F, L2026M) and off-target bypass pathways (MET amplification, HGF-mediated resistance, KRAS mutations, RET rearrangements) necessitate serial molecular profiling and rational TKI sequencing.
OpenScientist enumerates the same on-target mutation set and a broader off-target bypass landscape, matching the need for serial profiling.
PMID:38293020, PMID:37923925, PMID:36416133

ROS1 TKIs are the backbone of therapy, and next-generation agents (notably repotrectinib) deliver markedly prolonged progression-free survival in TKI-naive patients and retain activity against the G2032R resistance mutation.

UNANIMOUS INTEGRATED
treatmentprognosis
ProviderStanceScoreEvidence
falcon CONCORDANT 85% The preferred Food and Drug Administration-approved first-line therapies include crizotinib, entrectinib, and repotrectinib, and currently, selection amongst these options requires consideration of the systemic and CNS efficacy, tolerability, and access to therapy.
Falcon names repotrectinib among preferred first-line therapies, reports its 35.7-month TKI-naive median PFS, and documents activity against baseline G2032R (ORR 59%).
DOI:10.1093/oncolo/oyae205, DOI:10.1056/NEJMoa2302299
openscientist CONCORDANT 90% In the TKI-naive cohort (n = 71), 79% of patients achieved an objective response, with a median progression-free survival (PFS) of 35.7 months, surpassing all previously approved ROS1 TKIs
OpenScientist reports the same repotrectinib TKI-naive efficacy (ORR 79%, PFS 35.7 months) and describes taletrectinib activity against G2032R.
PMID:39402859, PMID:41548253

Co-occurring TP53 (and CDKN2A/B) alterations worsen prognosis in ROS1+ NSCLC; these tumors form an immunosuppressive, immune-cold microenvironment (high TMB but low CD8+ infiltration) that underlies limited checkpoint-inhibitor benefit.

MAJORITY LEAD
genetic_factorprognosistreatment
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% TP53/CDKN2A/B co-mutations (present in ~31% and ~15% respectively) create a paradoxical phenotype: high TMB and neoantigens but low CD8+ T-cell infiltration, resulting in worse prognosis.
OpenScientist links TP53/CDKN2A/B co-mutation to an immunosuppressive, immune-cold microenvironment and worse prognosis, and separately notes limited checkpoint-inhibitor activity.
PMID:37261522, PMID:34600407
falcon PARTIAL 40% are discussed as negatively impacting outcomes in review context (and were associated with numerically shorter outcomes in BFAST post hoc analyses)
Falcon flags TP53 co-alteration as a negative prognostic factor but does not describe the immunosuppressive microenvironment or checkpoint-inhibitor resistance mechanism.
DOI:10.1038/s41591-024-03008-4

Physiologically, ROS1 is a receptor tyrosine kinase acting in NELL2-mediated lumicrine signaling for epididymal epithelial differentiation (c-ros knockout mice are infertile), a pathway conserved in humans.

SINGLE LEAD
gene_function
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% ROS1 normally functions in NELL2-mediated epithelial differentiation; c-ros KO mice are infertile. This pathway is conserved in humans (correlation r = 0.604 between mouse and human ortholog expression).
OpenScientist details normal ROS1 function via NELL2 lumicrine signaling, the c-ros knockout infertility phenotype, and human conservation.
PMID:15109745, PMID:38169386
falcon SILENT —
Falcon does not address the normal physiological function of ROS1 or the NELL2 lumicrine signaling axis.

Narrative

Overview

Both providers frame ROS1-rearranged NSCLC as a rare, fusion-driven lung adenocarcinoma subtype (~1-2% of NSCLC) enriched in younger never-smoking women, with oncogene addiction to a constitutively active ROS1 kinase, high CNS tropism, a rapidly evolving ROS1 TKI landscape, and near-universal acquired resistance as the dominant clinical themes. Falcon is a therapy-and-trials-focused report; OpenScientist is a comprehensive 15-domain characterization that adds mechanistic and normal-biology depth.

Agreement

The reports converge on the core driver biology (somatic ROS1 fusion → constitutive, ligand-independent kinase → RTK effector signaling driving proliferation/survival), the demographic profile (younger, female, never-smoker), frequent brain metastases at diagnosis driving TKI choice, the resistance landscape (on-target G2032R and other kinase-domain mutations plus off-target MET bypass), and the primacy of next-generation ROS1 TKIs (repotrectinib TKI-naive median PFS 35.7 months) with activity against G2032R.

Divergence

OpenScientist uniquely elaborates the signaling mechanism — convergence of all ROS1 fusions on STAT3 and stronger SHP2 phosphorylation than ALK fusions (nominating SHP2 as a therapeutic vulnerability) — and the normal NELL2-ROS1 lumicrine biology, both of which Falcon is silent on. It also develops the TP53/CDKN2A/B immunosuppressive, immune-cold microenvironment and its link to limited checkpoint-inhibitor benefit, where Falcon notes only that TP53 co-alteration worsens outcomes. Falcon contributes denser late-breaking trial and real-world detail (TRIDENT-1, TRUST-I, BFAST Cohort D liquid-biopsy selection, ROS1REAL). The only quantitative divergences are minor and non-contradictory (baseline brain-metastasis fraction 20-40% vs 22-36%; frequency framed as 1-2.5% vs 1-2%).

Integration

Integrated into kb/disorders/ROS1_Rearranged_NSCLC.yaml: the ROS1-fusion driver and constitutive-kinase pathophysiology, the younger/female/ never-smoker demographic profile, frequent CNS involvement, the expanded resistance node (G2032R and other on-target mutations, MET amplification, HGF-MET bypass, serial profiling), and the ROS1 TKI treatment nodes with repotrectinib (macrocyclic, CNS-penetrant, TRIDENT-1) and taletrectinib (TKI-naive/pretreated, intracranial, G2032R) detail.

Not integrated (leads)

Retained as research leads rather than promoted: the SHP2/STAT3 convergence and SHP2-inhibitor combination rationale, the normal NELL2-ROS1 lumicrine biology, the TP53/CDKN2A/B immunosuppressive-microenvironment/immunotherapy interpretation, and emerging agents (zidesamtinib, cabozantinib for L2086F, unecritinib, APG-2449) and detailed adverse-event profiles.

Cross-provider synthesis comparing two independent deep-research reports for ROS1-rearranged NSCLC: falcon (Edison Scientific Literature, therapy/trials focused) and openscientist (autonomous, comprehensive 15-domain). No direct contradictions were identified; divergence is coverage/depth (OpenScientist adds SHP2/STAT3 signaling, normal NELL2 biology, and the immunosuppressive co-mutation microenvironment) plus minor quantitative differences (frequency and baseline brain-metastasis fraction). best_matching_text values are verbatim excerpts from the cited report files; literature evidence snippets are intentionally left to the main curation pipeline on the disorder YAML.